Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (2): 27-31.doi: 10.6040/j.issn.1671-7554.0.2021.1307
Previous Articles Next Articles
LIN Xueyan1, ZHANG Cancan2, TIAN Minle3, TIAN Yongjie1,4
CLC Number:
[1] Zhu TH, Zhang XM. Research progress on the role of epithelial-mesenchymal transition in pathogenesis of endometriosis [J]. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2016, 45(4): 439-445. [2] Yang YM, Yang WX. Epithelial-to-mesenchymal transition in the development of endometriosis [J]. Oncotarget, 2017, 8(25): 41679-41689. [3] Lutz Konrad, Raimund Dietze, Muhammad A Riaz, et al. Epithelial-mesenchymal transition in endometriosis-when does it happen? [J]. Clin Med, 2020, 9(6): 1915. doi: 10.3390/jcm9061915. [4] Su Shan, Lin XY, Ding N, et al. Effects of PARP-1 inhibitor and ERK inhibitor on epithelial mesenchymal transitions of the ovarian cancer SKOV3 cells [J]. Pharmacol Rep, 2016, 68(6): 1225-1229. [5] Wei W, Lv SQ, Zhang CC, et al. PARP-1 may be involved in angiogenesis in epithelial ovarian cance r[J]. Oncol Lett, 2016, 12(6): 4561-4567. [6] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition [J]. Nat Rev Mol Cell Biol, 2014, 15(3): 178-196. [7] Biyik I, Kalkan U, Simsek S. The deep infiltrating endometriosis tissue has lower T-cadherin, E-cadherin, progesterone receptor and oestrogen receptor than endometrioma tissue [J]. Taiwan J Obstet Gynecol, 2021, 60(6): 1059-1065. [8] Batlle E, Sancho E, Francí C, et al.The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells [J]. Nat Cell Biol, 2000, 2(2): 84-89. [9] Garinet S, Didelot A, Denize T, et al. Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC [J]. Br J Cancer, 2021, 125(11): 1544-1551. [10] Cano A, Pérez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression [J]. Nat Cell Biol, 2000, 2(2): 76-83. [11] Xi L, Yang J, Wang X, et al. Role of TWIST2, E-cadherin and Vimentin in epithelial ovarian carcinogenesis and prognosis and their interaction in cancer progression [J]. Eur J Gynaecol Oncol, 2016, 37(1): 100-108. [12] Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells [J]. Clin Cancer Res, 2005, 11(22): 8006-8014. [13] Scotti S, Regidor PA, Schindler AE, et al. Reduced proliferation and cell adhesion in endometriosis [J]. Mol Hum Reprod, 2000, 6(7): 610-617. [14] Zhu H, Wei M, Xu J, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications [J]. Mol Cancer, 2020,19(1): 49. doi: 10.1186/s12943-020-01167-9. [15] Wei W, Li Y, Lv SQ, et al. PARP-1 may be involved in angiogenesis in epithelial ovarian cancer [J]. Oncol Lett, 2016, 12(6): 4561-4567. [16] Bahar E, Kim JY, Kim HS, et al. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression [J]. Int J Mol Sci, 2020, 21(20):7613. [17] Scutiero G, Iannone P, Bernardi G, et al. Oxidative stress and endometriosis: a systematic review of the literature [J]. Oxid Med Cell Longev, 2017, 2017: 7265238. [18] 郑玉梅, 彭超, 陆叶, 等. 深部浸润型子宫内膜异位症在盆腔子宫内膜异位症中的发生率及其临床病理特征分析[J]. 中华妇产科杂志, 2020, 55(6): 384-389. ZHENG Yumei, PENG Chao, LU Ye, et al. Incidence of deeply infiltrating endometriosis among 240 cases of pelvic endometriosis and analysis of its clinical and pathological characteristics [J]. Chinese Journal of Obstetrics and Gynecology, 2020, 55(6): 384-389. [19] Béliard A, Donnez J, Nisolle M, et al. Localization of laminin, fibronectin, E-cadherin, and integrins in endometrium and endometriosis [J]. Fertil Steril, 1997, 67(2): 266-272. [20] Shaco-Levy R, Sharabi S, Benharroch D, et al. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium [J]. Eur J Obstet Gynecol Reprod Biol, 2008, 139(2): 226-232. [21] Pu H, Horbinski C, Hensley PJ, et al. PARP-1 regulates epithelial-mesenchymal transition(EMT)in prostate tumorigenesis [J]. Carcinogenesis, 2014, 35(11): 2592-2601. [22] Lin Y, Kang T, Zhou BP. Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a PARP1-dependent manne r[J]. Cell Cycle, 2014, 13(11): 1708-1716. [23] McPhee TR, McDonald PC, Oloumi A, et al. Integrin-linked kinase regulates E-cadherin expression through PARP-1 [J]. Dev Dyn, 2008, 237(10): 2737-2747. [24] Chu S, Xu H, Ferro TJ, et al. Poly(ADP-ribose)polymerase-1 regulates vimentin expression in lung cancer cells [J]. Am J Physiol Lung Cell Mol Physiol, 2007, 293(5): L1127-L1134. [25] Kumar M, Jaiswal RK, Yadava PK, Singh RP. An assessment of poly(ADP-ribose)polymerase-1 role in normal and cancer cells [J]. Biofactors, 2020, 46(6): 894-905. |
[1] | Lei YAN,Caixin YUE,Yichun LIU. Fertility preservation in patients with endometriosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 31-34. |
[2] | Jinhua LENG,Jinghua SHI. Clinical manifestations of adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 1-5. |
[3] | CHEN Zhongshao, CHU Ran, LI Mingbao, ZHANG Xiangning. MRKH syndrome-related abdominal scar endometriosis after inguinal uterine hernia repair: a case report and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 114-117. |
[4] | XU Ge, LI Qing, ZHANG Cancan, TIAN Yongjie. Expressions and clinical significance of PARP-1 and HIF-1α in adenomyosis tissues and primary cells [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 55-61. |
[5] | SHAN Jing, WANG Xiaoqiu, LI Dajin. Molecular mechanisms of NK cells involved in endometriosis and its associated infertility [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 8-13. |
[6] | LIANG Yanchun, YE Haihua, LU Limei, DAI Yujing, CHENG Qianyi, CHOI Unleng, ZENG Hanqiu, CHEN Xinghuan, WANG Xing, WEI Yajing, YANG Ruyu. Effects of chronic endometritis on the pregnancy outcomes of patients with endometriosis-associated infertility [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 55-59. |
[7] | XUE Yuan, LIN Xueyan, XU Ge, TIAN Yongjie. Expression of hypoxia-inducible factor-1α in the serum of patients with endometriosis and its effect on epithelial mesenchymal transition of eutopic endometrial stromal cells [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 41-47. |
[8] | Endometriosis and Chronic Pelvic Pain Training Center of Shandong Medical Doctor AssociationWANG Guoyun, WANG Kai, YUAN Ming, CHEN Zijiang. Multidimensional management system for endometriosis (The Program for Shandong Province) [J]. Journal of Shandong University (Health Sciences), 2021, 59(10): 1-17. |
[9] | LU Jingjing, XIA Yu. Imaging diagnosis of endometriosis [J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 40-45. |
[10] | LIU Chongdong, LOU Tong, DONG Jing. Malignant transformation of endometriosis [J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 27-32. |
[11] | HUANG Wei, LIU Dong. Fertility improvement strategies for endometriosis associated infertility [J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 23-26. |
[12] | YAO Shuzhong, LIANG Yanchun, WEI Yajing. Surgical treatment of endometriosis [J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 6-15. |
[13] | ZHANG Xinmei, QIAN Honglang. Clinical manifestations of endometriosis [J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 16-22. |
[14] | PENG Chao, ZHOU Yingfang. Medical treatment of endometriosis: an update [J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 46-50. |
[15] | WANG Guoyun, YUAN Ming, JI Miaomiao. Research advances in the pathogenesis of endometriosis [J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 33-39. |
|